Immunic (IMUX) Competitors $0.93 -0.01 (-0.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.94 +0.01 (+0.81%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. ABEO, CYRX, AURA, PRTA, PVLA, FHTX, RCKT, INBX, ALT, and TNXPShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Abeona Therapeutics (ABEO), CryoPort (CYRX), Aura Biosciences (AURA), Prothena (PRTA), Palvella Therapeutics (PVLA), Foghorn Therapeutics (FHTX), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), Altimmune (ALT), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Abeona Therapeutics CryoPort Aura Biosciences Prothena Palvella Therapeutics Foghorn Therapeutics Rocket Pharmaceuticals Inhibrx Biosciences Altimmune Tonix Pharmaceuticals Abeona Therapeutics (NASDAQ:ABEO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Is ABEO or IMUX more profitable? Abeona Therapeutics' return on equity of -118.82% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A -118.82% -52.48% Immunic N/A -326.95%-181.34% Does the media refer more to ABEO or IMUX? In the previous week, Abeona Therapeutics had 1 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Abeona Therapeutics and 3 mentions for Immunic. Immunic's average media sentiment score of 0.80 beat Abeona Therapeutics' score of 0.20 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunic 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ABEO or IMUX? Abeona Therapeutics presently has a consensus target price of $19.25, indicating a potential upside of 196.61%. Immunic has a consensus target price of $7.50, indicating a potential upside of 705.15%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Abeona Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Do institutionals & insiders believe in ABEO or IMUX? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.6% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, ABEO or IMUX? Abeona Therapeutics has higher revenue and earnings than Immunic. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M94.87-$63.73M-$1.27-5.11ImmunicN/AN/A-$100.51M-$1.23-0.76 Which has more risk & volatility, ABEO or IMUX? Abeona Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, Immunic has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. SummaryAbeona Therapeutics beats Immunic on 8 of the 14 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.08M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.7617.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book4.668.508.275.54Net Income-$100.51M-$55.06M$3.25B$259.28M7 Day Performance-16.83%-3.99%-3.70%-4.64%1 Month Performance30.65%9.58%4.34%4.41%1 Year Performance-27.79%6.70%25.90%17.95% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.9811 of 5 stars$0.93-0.9%$7.50+705.2%-33.5%$90.08MN/A-0.7670News CoverageUpcoming EarningsGap DownABEOAbeona Therapeutics3.8538 of 5 stars$6.73+2.1%$19.25+186.0%+34.9%$345.33M$3.50M-5.3190News CoverageCYRXCryoPort2.1548 of 5 stars$6.81-5.4%$10.88+59.8%-16.4%$344.21M$228.38M-2.931,186Upcoming EarningsAURAAura Biosciences1.556 of 5 stars$6.84+1.9%$22.00+221.6%-31.6%$343.60MN/A-3.6050Gap DownPRTAProthena3.2473 of 5 stars$6.34+1.3%$31.50+396.9%-69.5%$341.80M$137.94M-3.05130News CoverageUpcoming EarningsPVLAPalvella Therapeutics2.6822 of 5 stars$30.84+4.5%$47.50+54.0%N/A$341.09M$42.81M-2.55N/AFHTXFoghorn Therapeutics2.4956 of 5 stars$6.11-0.4%$12.13+98.6%-23.3%$340.29M$22.60M-4.49120Upcoming EarningsGap DownRCKTRocket Pharmaceuticals4.8355 of 5 stars$3.12+2.5%$18.60+497.1%-86.5%$334.79MN/A-1.19240Trending NewsUpcoming EarningsINBXInhibrx Biosciences1.3548 of 5 stars$22.79-6.8%N/A+48.2%$332.75M$200K0.20166ALTAltimmune2.2452 of 5 stars$4.08-0.1%$18.20+346.6%-40.7%$331.33M$20K-3.2450Upcoming EarningsTNXPTonix Pharmaceuticals3.4312 of 5 stars$44.82-4.5%$585.00+1,205.4%-24.9%$329.26M$10.04M-0.0250Analyst RevisionGap Down Related Companies and Tools Related Companies Abeona Therapeutics Alternatives CryoPort Alternatives Aura Biosciences Alternatives Prothena Alternatives Palvella Therapeutics Alternatives Foghorn Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Inhibrx Biosciences Alternatives Altimmune Alternatives Tonix Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMUX Stock Alerts